Catabasis Pharmaceuticals, Inc. webinar “MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy”
CureDuchenne and Catabasis Pharmaceuticals, Inc. hosted a webinar “MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy” on Wednesday, June 22, 2016.
Dr. Donovan discussed the positive results from Part A of the MoveDMD trial and reviewed the design and inclusion criteria of Part B (Phase 2) that is currently running. The MoveDMD trial is a Phase 1/2 clinical trial of edasalonexent in boys with Duchenne between the ages of 4 and 7. The goal of Part A included evaluation of the safety and tolerability of edasalonexent. Part B will evaluate the safety and efficacy of edasalonexent in boys with Duchenne.
Dr. Donovan, who received her academic training at MIT, Harvard and Brigham & Women’s Hospital, has more than 15 years of experience in drug development, taking programs from Phase 1 to approval. Dr. Donovan is currently an Associate Clinical Professor of Medicine at Harvard and continues to practice and teach medicine.
- Dr. Joanne Donovan, Chief Medical Officer, Catabasis
- Debra Miller, Founder and CEO, CureDuchenne
- Dr. Michael Kelly, Chief Scientific Advisor, CureDuchenne
Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.